ClinicalTrials.gov
ClinicalTrials.gov Menu

Melatonin Study Between Diminished and Normal Responder in IVF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03117725
Recruitment Status : Not yet recruiting
First Posted : April 18, 2017
Last Update Posted : April 18, 2017
Sponsor:
Information provided by (Responsible Party):
Dong Hee Choi, Bundang CHA Hospital

Brief Summary:
Poor sleep quality may lead to increase in oxidative stress and free radicals which in turn may decrease the reproductive function. Many researchers have already proven improvement on reproductive function after antioxidant (melatonin) administration. The investigators wish to study the relationship between unexplained, young poor ovarian responder and oxidative stress.

Condition or disease Intervention/treatment Phase
Infertility, Female Drug: Melatonin adminstration Drug: placebo administration Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Comparison of IVF Outcome and Endometrium Effect in Infertility Patients Between Diminished and Normal Ovarian Reserve After Melatonin Administration.
Estimated Study Start Date : April 30, 2017
Estimated Primary Completion Date : December 30, 2017
Estimated Study Completion Date : February 28, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

Arm Intervention/treatment
Experimental: melatonin administration group

Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants for melatonin administration are to go under melatonin admisitration intervention from the time of COH to the date of oocyte retrieval. . If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.

For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval.

Drug: Melatonin adminstration
The drug, melatonin will be takenevery night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.

Placebo Comparator: placebo comparator

Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.

For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval.

Drug: placebo administration
the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.




Primary Outcome Measures :
  1. IVF outcome - oocyte quality [ Time Frame: 3 days after oocyte retrieval ]
    Evaluate oocyte quality on morphological standard as follwing catagory- Mature oocyte, Imtermediate oocyte, atretic oocyte, post mature oocyte

  2. IVF outcome - embryo quality [ Time Frame: 3 to 5 days after oocyteretrieval ]
    grade the embryos& blastocysts according to the Lucinda Veeck & Gardner

  3. IVF outcome -biochemical pregnancy rate [ Time Frame: on day 12~14 after embyo transfer ]
    serum hCG level>10 IU

  4. IVF outcome - clinical pregnancy rate [ Time Frame: at 6-8 weeks of gestation ]
    presence of G-sac in the uterine cavity


Secondary Outcome Measures :
  1. acquired oocyte No [ Time Frame: 20weeks ]
    number

  2. fertilization rate [ Time Frame: 20weeks ]
    ratio of no. of fertilized egg/ no of total retreived eggs

  3. Compairing Pittsburgh sleep quality index [ Time Frame: 20weeks ]
    questionairs to evaluate the participants quality of the sleep. cut off : 13 points This questionaire is to be asked to the participants twice, before and after the administration of the drug

  4. marker(melatonin level, receptor, 8-OHdg) in serum, follicular fluid and endometrium during IVF [ Time Frame: 20weeks ]
    :pg/ml units are used



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Infertility patients visiting Bundang CHA hospital between the age of 20 to 40.
  2. Currently, not being treated for any gynecological or medical diseases.

Exclusion Criteria:

  1. Current untreated pelvic pathology (moderate-to-severe endometriosis, submucosal uterine fibroids/polyps assessed by the treating specialist to affect fertility, pelvic inflammatory disease,uterine malformations, and hydrosalpinx.)
  2. Currently enrolled in another interventional clinical trial.
  3. Concurrent use of other adjuvant therapies (e.g.Chinese herbs, acupuncture).
  4. Autoimmune disorders.
  5. Undergoing preimplantation genetic diagnosis.
  6. Concurrent use of any of the following medications (Fluvoxamine,Cimetidine, Quinolones, Carbamazepine, rifampicin,Zolpidem, zopiclone, and other non-benzodiazepine hypnotic, other CYP1A2 inducers.
  7. Genetic disorders regarding galactose intolerance, lactase deficiency, glucose-galactose malabsorption
  8. Inability to comply with trial protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117725


Contacts
Contact: JI EUN SHIN, M.D 82-11-9616-1114 1219annie@cha.ac.kr
Contact: JI EUN SHIN, M.D 82-31-780-5200 1219annie@cha.ac.kr

Sponsors and Collaborators
Bundang CHA Hospital
Investigators
Principal Investigator: DONG HEE CHOI, M.D,Ph.D BUNDANGCHA HOSPITAL

Study Data/Documents: Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: 31098

Publications:
Responsible Party: Dong Hee Choi, M.D, Ph.D, Bundang CHA Hospital
ClinicalTrials.gov Identifier: NCT03117725     History of Changes
Other Study ID Numbers: 2016-07-013-008
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: April 18, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dong Hee Choi, Bundang CHA Hospital:
oxidative stress
antioxidants
diminished ovarian reserve

Additional relevant MeSH terms:
Infertility
Infertility, Female
Genital Diseases, Male
Genital Diseases, Female
Melatonin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants